Galectin Therapeutics Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $3,531,000 for the third quarter and reporting significant changes to its balance sheet following the conversion of related-party debt to common stock.

Key Highlights

  • Net loss of $3,531,000 for the three months ended September 30, 2026, compared to a net loss of $8,184,000 in the same period of 2025, according to the filing.
  • Nine-month net loss of $17,690,000 for the period ended September 30, 2026, versus $25,336,000 for the same period in 2025, the filing disclosed.
  • Cash and cash equivalents of $11,706,000 at September 30, 2026, down from $17,720,000 at December 31, 2025, the company reported.
  • $105,230,000 in related-party convertible debt was converted to common stock as a noncash financing activity during the nine months ended September 30, 2026, per the filing.
  • Common shares outstanding increased to 100,875,106 as of November 6, 2026, from 65,201,995 at December 31, 2025, according to the filing.
  • Accumulated deficit reached $450,356,000 at September 30, 2026, compared to $432,546,000 at December 31, 2025, the filing stated.

Galectin Therapeutics Q3 2026 Financial Results and Balance Sheet Changes

Galectin Therapeutics Inc. (NASDAQ:GALT), a smaller reporting company incorporated in Nevada and headquartered in Norcross, Georgia, reported a net loss of $3,531,000 for the three months ended September 30, 2026, compared to a net loss of $8,184,000 for the same quarter a year earlier, according to the quarterly filing. Total operating expenses for the third quarter were $3,367,000, consisting of $1,564,000 in research and development costs and $1,803,000 in general and administrative expenses. For the same quarter in 2025, total operating expenses were $4,198,000, the filing showed.

For the nine months ended September 30, 2026, the company reported a net loss of $17,690,000 and total operating expenses of $11,426,000, compared to a net loss of $25,336,000 and total operating expenses of $16,720,000 for the same period in 2025. Research and development spending for the nine-month period declined to $5,930,000 from $12,357,000 in the prior year period, while general and administrative expenses increased to $5,496,000 from $4,363,000, the filing disclosed. Net cash used in operating activities for the nine months ended September 30, 2026 was $8,570,000, compared to $17,833,000 in the year-earlier period.

A notable balance sheet development disclosed in the filing was the conversion of $105,230,000 in related-party convertible debt to common stock during the nine months ended September 30, 2026, recorded as a noncash financing activity. This contributed to total current liabilities falling to $46,406,000 at September 30, 2026, from $145,727,000 in total liabilities at December 31, 2025, and reduced the total stockholders' deficit to $35,162,000 from $127,918,000 over the same period. The company also reported derivative liabilities of $5,541,000 as a current liability at September 30, 2026. Additional paid-in capital increased to $414,614,000 from $304,073,000 at December 31, 2025, reflecting the debt conversion and other equity activity during the period.

What Was Disclosed

Galectin Therapeutics filed its 10-Q for Q3 2026, reporting a $3,531,000 quarterly net loss, $11,706,000 in cash, and a $105,230,000 noncash conversion of related-party convertible debt into common stock, which materially reduced total liabilities and the stockholders' deficit.